Byam Rebecca's most recent trade in HCW Biologics Inc was a trade of 8,462 Common Stock done at an average price of $26 . Disclosure was reported to the exchange on May 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 26.00 per share. | 07 May 2025 | 8,462 | 43,010 | - | 26 | 220,012 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 07 May 2025 | 4,231 | 4,231 | - | - | Common Stock Purchase Warrant | |
| HCW Biologics Inc | Byam Rebecca | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.40 per share. | 20 Feb 2024 | 760,714 | 1,381,909 | - | 1.4 | 1,065,000 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.06 per share. | 09 Jun 2023 | 20,000 | 543,946 | - | 2.1 | 41,286 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.03 per share. | 07 Jun 2023 | 20,000 | 519,250 | - | 2.0 | 40,632 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.21 per share. | 07 Jun 2023 | 4,696 | 523,946 | - | 2.2 | 10,388 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.67 per share. | 05 Jun 2023 | 20,000 | 480,188 | - | 1.7 | 33,344 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.82 per share. | 05 Jun 2023 | 19,062 | 499,250 | - | 1.8 | 34,779 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.66 per share. | 25 May 2023 | 20,000 | 460,188 | - | 1.7 | 33,196 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.62 per share. | 25 May 2023 | 20,000 | 440,188 | - | 1.6 | 32,348 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.53 per share. | 22 May 2023 | 33,450 | 395,152 | - | 1.5 | 51,045 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.61 per share. | 22 May 2023 | 20,000 | 420,188 | - | 1.6 | 32,150 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 22 May 2023 | 5,036 | 400,188 | - | 1.6 | 7,887 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.14 per share. | 02 Nov 2022 | 33,750 | 361,702 | - | 0.1 | 4,725 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2022 | 33,750 | 47,249 | - | - | Stock Option Grant (Right to Buy) | |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.58 per share. | 14 Sep 2022 | 15,000 | 327,952 | - | 2.6 | 38,651 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.58 per share. | 12 Sep 2022 | 15,000 | 312,952 | - | 2.6 | 38,651 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.65 per share. | 12 Sep 2022 | 15,000 | 297,952 | - | 2.7 | 39,764 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.56 per share. | 30 Aug 2022 | 10,000 | 282,952 | - | 2.6 | 25,572 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 30 Aug 2022 | 7,200 | 272,952 | - | 2.5 | 18,341 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.57 per share. | 26 Aug 2022 | 10,000 | 265,752 | - | 2.6 | 25,662 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.54 per share. | 26 Aug 2022 | 10,000 | 255,752 | - | 2.5 | 25,358 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 24 Aug 2022 | 50,000 | 205,452 | - | 2.5 | 125,225 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.59 per share. | 24 Aug 2022 | 40,300 | 245,752 | - | 2.6 | 104,522 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.46 per share. | 13 Jun 2022 | 58,856 | 155,452 | - | 2.5 | 144,986 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.08 per share. | 13 Jun 2022 | 7,596 | 96,596 | - | 2.1 | 15,813 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.14 per share. | 23 Nov 2021 | 27,000 | 89,000 | - | 0.1 | 3,780 | Common Stock |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 27,000 | 80,999 | - | - | Stock Option Grant (Right to Buy) | |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2021 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| HCW Biologics Inc | Rebecca Byam | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.40 per share. | 19 Aug 2021 | 10,000 | 62,000 | - | 4.4 | 43,979 | Common Stock |